Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 28, 2016; 22(44): 9661-9673
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9661
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9661
Table 4 Summary of studies concerning irreversible ablation
Authors | Number of patients | Lesion | Location | Treatment type | Approach | Needle | Mean treatment duration | Conclusion |
Bagla et al[72] | 1 | Pancreatic ductal adenocarcinoma | Body-tail | Irreversible electroporation | Percutaneous with US and CT | 22 G | - | Percutaneous IRE showed promise as a feasible and potentially safe method for unresectable tumor |
Martin et al[73] | 27 | Pancreatic ductal adenocarcinoma | 15 head + 12 body-tail | Irreversible electroporation | 1 percutaneous + 26 surgical | - | - | IRE ablation is safe and feasible as a primary local treatment in unresectable locally advanced disease |
Narayanan et al[10] | 14 | Pancreatic ductal adenocarcinoma | 6 head + 1 uncinated process + 7 body-tail | Irreversible electroporation | Percutaneous with CT | - | - | Percutaneous IRE in pancreatic adenocarcinoma is feasible and safe |
Månsson et al[11] | 24 | Pancreatic ductal adenocarcinoma | 19 head + 5 body-tail | Irreversible electroporation | Percutaneous with US | - | - | Percutaneous IRE is reasonably safe and shows promising results for efficacy |
- Citation: D’Onofrio M, Ciaravino V, De Robertis R, Barbi E, Salvia R, Girelli R, Paiella S, Gasparini C, Cardobi N, Bassi C. Percutaneous ablation of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9661-9673
- URL: https://www.wjgnet.com/1007-9327/full/v22/i44/9661.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i44.9661